drugset / Trial / NCT06391190
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
To explore the safety and efficacy of Albumin-Bound Paclitaxel/Platinum based concurrent chemoradiotherapy Followed by PD-1 inhibitor (Sintilimab) in locally advanced cervical cancer
Timeline
- Start
- 2022-01-01
- Primary completion
- 2024-12-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin-Bound Paclitaxel | Unknown | 50 mg/m2 | — |
| Subject | Albumin-Bound Paclitaxel | Unknown | 75 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 40 mg/m2 | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |